Evofem Biosciences Inc
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recur… Read more
Market Cap & Net Worth: Evofem Biosciences Inc (EVFM)
Evofem Biosciences Inc (OTCQB:EVFM) has a market capitalization of $1.13 Million ($1.13 Million) as of March 18, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #36003 globally and #11708 in its home market, demonstrating a 11.11% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Evofem Biosciences Inc's stock price $0.01 by its total outstanding shares 113356000 (113.36 Million).
Evofem Biosciences Inc Market Cap History: 2015 to 2025
Evofem Biosciences Inc's market capitalization history from 2015 to 2025. Data shows change from $1.77 Trillion to $1.13 Million (-81.75% CAGR).
Evofem Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Evofem Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.06x
Evofem Biosciences Inc's market cap is 0.06 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $512.23 Billion | $446.00K | -$142.31 Million | 1148491.98x | N/A |
| 2021 | $79.81 Billion | $8.24 Million | -$205.19 Million | 9680.94x | N/A |
| 2022 | $906.85 Million | $16.84 Million | -$76.70 Million | 53.86x | N/A |
| 2023 | $7.25 Million | $18.22 Million | $52.98 Million | 0.40x | 0.14x |
| 2024 | $1.13 Million | $19.36 Million | -$8.86 Million | 0.06x | N/A |
Competitor Companies of EVFM by Market Capitalization
Companies near Evofem Biosciences Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Evofem Biosciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Evofem Biosciences Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Evofem Biosciences Inc's market cap moved from $1.77 Trillion to $ 1.13 Million, with a yearly change of -81.75%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $1.13 Million | 0.00% |
| 2024 | $1.13 Million | -84.38% |
| 2023 | $7.25 Million | -99.20% |
| 2022 | $906.85 Million | -98.86% |
| 2021 | $79.81 Billion | -84.42% |
| 2020 | $512.23 Billion | -60.94% |
| 2019 | $1.31 Trillion | +47.26% |
| 2018 | $890.55 Billion | -64.19% |
| 2017 | $2.49 Trillion | +74.11% |
| 2016 | $1.43 Trillion | -19.42% |
| 2015 | $1.77 Trillion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Evofem Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.13 Million USD |
| MoneyControl | $1.13 Million USD |
| MarketWatch | $1.13 Million USD |
| marketcap.company | $1.13 Million USD |
| Reuters | $1.13 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.